PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-57.23%
Negative revenue growth while TRAW stands at 1.79%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-57.23%
Negative gross profit growth while TRAW is at 1.79%. Joel Greenblatt would examine cost competitiveness or demand decline.
5.53%
Positive EBIT growth while TRAW is negative. John Neff might see a substantial edge in operational management.
5.53%
Positive operating income growth while TRAW is negative. John Neff might view this as a competitive edge in operations.
5.62%
Net income growth at 50-75% of TRAW's 10.27%. Martin Whitman would question fundamental disadvantages in expenses or demand.
13.79%
EPS growth at 75-90% of TRAW's 15.62%. Bill Ackman would push for improved profitability or share repurchases to catch up.
13.79%
Diluted EPS growth at 75-90% of TRAW's 15.62%. Bill Ackman would expect further improvements in net income or share count reduction.
10.10%
Share count expansion well above TRAW's 7.97%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.10%
Diluted share count expanding well above TRAW's 7.97%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
18.75%
OCF growth at 50-75% of TRAW's 35.21%. Martin Whitman would question if the firm lags in monetizing sales effectively.
17.73%
FCF growth 50-75% of TRAW's 35.21%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1028.36%
Negative 10Y OCF/share CAGR while TRAW stands at 99.97%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
94.36%
5Y OCF/share CAGR is similar to TRAW's 99.92%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
80.21%
3Y OCF/share CAGR at 75-90% of TRAW's 98.40%. Bill Ackman would press for improvements in margin or overhead to catch up.
-551.14%
Negative 10Y net income/share CAGR while TRAW is at 99.98%. Joel Greenblatt sees a major red flag in long-term profit erosion.
94.20%
5Y net income/share CAGR similar to TRAW's 99.94%. Walter Schloss might see both on parallel mid-term trajectories.
81.22%
3Y net income/share CAGR 75-90% of TRAW's 98.38%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1992.70%
Equity/share CAGR of 1992.70% while TRAW is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-67.70%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-15.48%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Positive asset growth while TRAW is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.36%
Positive BV/share change while TRAW is negative. John Neff sees a clear edge over a competitor losing equity.
-16.56%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-15.08%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-0.47%
We cut SG&A while TRAW invests at 28.55%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.